Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RVU 120

Next Previous
Drug Profile

RVU 120

Alternative Names: RVU-120; SEL-120; SEL120-34; SEL120-34A

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selvita
  • Developer Ryvu Therapeutics
  • Class Antineoplastics; Halogenated hydrocarbons; Imidazoles; Piperazines; Quinolones; Small molecules
  • Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I/II Solid tumours
  • Preclinical Breast cancer; Myeloproliferative disorders

Most Recent Events

  • 03 May 2025 Ryvu Therapeutics plans a phase II trial for Acute myeloid leukaemia, Myelodysplastic syndromes and Solid tumours in the Poland and Spain (NCT06987058)
  • 13 Mar 2025 Ryvu Therapeutics suspends enrolment in the RIVER-52 trial for Acute myeoid leukemia and Myelodysplastic syndrome in Canada, France, Italy, Poland and Spain
  • 12 Dec 2024 Efficacy and adverse events data from a phase II RIVER-81 trial in Acute myeloid leukaemia released by Ryvu Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top